A Phase 2 Study of the ALK Inhibitor Ensartinib for Patients With Melanomas Harboring ALK Alterations or Aberrant ALK Expression
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Jan 2020
Price : $35 *
At a glance
- Drugs Ensartinib (Primary)
- Indications Brain metastases; Malignant melanoma; Uveal melanoma
- Focus Therapeutic Use
- 22 Jan 2020 Status changed from recruiting to active, no longer recruiting.
- 03 Jan 2020 Planned End Date changed from 1 Jan 2020 to 1 Jan 2021.
- 03 Jan 2020 Planned primary completion date changed from 1 Jan 2020 to 1 Jan 2021.